-- EQT AB and KKR (KKR) are among private equity firms showing takeover interest in PolyPeptide Group, Bloomberg reported Friday, citing people with knowledge of the matter.
Advent has also been reviewing a possible acquisition of the Swiss contract drugmaker, the report said.
EQT and KKR didn't immediately reply to requests for comment from.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: $90.26, Change: $-2.58, Percent Change: -2.77%